Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML

被引：0
作者：
C F Craddock
机构：
[1] Centre for Clinical Haematology,
[2] University Hospital Birmingham NHS Trust,undefined
[3] Institute of Cancer Studies,undefined
[4] University of Birmingham,undefined
来源：
Bone Marrow Transplantation | 2008年 / 41卷
关键词：
AML; reduced-intensity conditioning; GVL;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Allogeneic stem cell transplantation represents the most active form of anti-leukaemic therapy in acute myeloid leukaemia (AML). Advances in transplant technology and supportive care have resulted in improved outcomes in patients allografted using a myeloablative conditioning regimen. At the same time the use of reduced-intensity conditioning regimens has allowed an immunologically mediated graft-versus-leukaemia effect to be exploited in older patients who were previously ineligible for transplantation on the grounds of age or comorbidity. This coupled with the increased availability of alternative stem cell sources, in the form of either unrelated or cord blood donations, has established allogeneic transplantation as a key therapeutic strategy in the treatment of both younger and older adults with AML.
引用
收藏
页码：415 / 423
页数：8
相关论文
共 545 条
[1]  
Gratwohl A(2006)EBMT activity survey 2004 and changes in disease indication over the past 15 years Bone Marrow Transplantation 37 1069-1085
[2]  
Baldomero H(2005)Treatment of older patients with AML Crit Rev Oncol Hematol 56 247-259
[3]  
Frauendorfer K(1997)Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study Blood 89 3323-3329
[4]  
Urbano-Ispizua A(2001)The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial Blood 98 1312-1320
[5]  
Buchner T(2006)Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B Blood 108 3280-3288
[6]  
Berdel WE(2007)Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 109 3658-3666
[7]  
Wormann B(2004)Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors Blood 103 435-441
[8]  
Schoch C(2004)Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation Blood 104 865-872
[9]  
Haferlach T(2006)Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors J Clin Oncol 24 444-453
[10]  
Schnittger S(2005)Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia J Clin Oncol 23 9387-9393
12345678910